GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (FRA:08D) » Definitions » Selling, General, & Admin. Expense

Mirum Pharmaceuticals (FRA:08D) Selling, General, & Admin. Expense : €149.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Mirum Pharmaceuticals Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Mirum Pharmaceuticals's selling, general, & admin. expense for the three months ended in Mar. 2024 was €42.0 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2024 was €149.0 Mil.


Mirum Pharmaceuticals Selling, General, & Admin. Expense Historical Data

The historical data trend for Mirum Pharmaceuticals's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirum Pharmaceuticals Selling, General, & Admin. Expense Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 10.58 18.65 52.41 84.08 133.77

Mirum Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.23 30.41 34.23 42.35 41.99

Competitive Comparison of Mirum Pharmaceuticals's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Mirum Pharmaceuticals's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mirum Pharmaceuticals's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Mirum Pharmaceuticals's Selling, General, & Admin. Expense falls into.



Mirum Pharmaceuticals Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €149.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mirum Pharmaceuticals  (FRA:08D) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Mirum Pharmaceuticals Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Mirum Pharmaceuticals's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Mirum Pharmaceuticals (FRA:08D) Business Description

Industry
Traded in Other Exchanges
Address
950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Mirum Pharmaceuticals (FRA:08D) Headlines

No Headlines